-
Prostate: Investigation of predictors of recurrence in holmium laser enucleation of prostate
Time of Update: 2021-12-04
Recently, researchers from Italy published an article in "Prostate" to evaluate the long-term outcome, recurrence rate of symptoms and predictive factors of patients receiving HoLEP .
Evaluated the long-term outcome, symptom recurrence rate, and predictors of patients receiving HoLEP.
-
NEJM: The overall survival benefit of Tebentafusp for metastatic uveal melanoma
Time of Update: 2021-12-04
Changes in the incidence of treatment-related adverse eventsAll in all, compared with the control treatment, Tebentafusp treatment prolonged the overall survival of previously untreated patients with metastatic uveal melanoma .
Compared with the control treatment, Tebentafusp treatment prolonged the overall survival of previously untreated patients with metastatic uveal melanoma .
-
Clin Lymphoma Myeloma Leuk: Infectious complications in AML patients treated with immune checkpoint inhibitors
Time of Update: 2021-12-04
With great success in the treatment of various solid tumors and lymphomas , immune checkpoint inhibitors (CPIs) are currently being studied as an immunotherapy option for patients with acute myeloid leukemia (AML) .
-
How many of the "high-risk behaviors" that make the onset of colorectal cancer younger?
Time of Update: 2021-12-04
Risk factors and disease sitesBy assessing the risk of early-onset CRC by cancer sub-sites (Table 3), it can be found that irregular use of non-steroidal anti-inflammatory drugs, more red meat intake, lower dietary fiber intake, and lower folic acid intake Intake, lower calcium intake, abstinence and heavy drinking ( > 28 g/day), and lower education are all related to the high risk of early-onset CRC of the rectum and colon .
-
ESMO Open: A first-line regimen of paclitaxel combined with carboplatin plus bevacizumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma
Time of Update: 2021-12-04
In the first-line regimen of paclitaxel combined with carboplatin, the addition of bevacizumab cannot prolong the progression-free survival and overall survival of patients with recurrent or metastatic nasopharyngeal carcinoma, but it can increase the tumor shrinkage rate .
-
Clin Cancer Res: The relationship between the neutrophil/lymphocyte ratio (NLR) and the efficacy of avelumab combined with axitinib or sunitinib in the treatment of advanced renal cell carcinoma (RCC): from the JAVELIN Renal 101 study
Time of Update: 2021-12-04
SunitinibThrough the analysis of the JAVELIN Renal 101 clinical study (NCT02684006), the relationship between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab combined with axitinib or sunitinib group was analyzed Retrospective analysis .
-
It's not this fishbone, this stomach cancer will probably be delayed!
Time of Update: 2021-12-04
Quality of LifeFor early-stage cancers like Lv, the 5-year survival rate reaches 90%-97%, and it has been reported that intramucosal cancer can reach 100%; while advanced gastric cancer is only about 15% .
-
eLife: How did small moles become melanoma from cancer?
Time of Update: 2021-12-04
Colon cancer lung cancerThe previous mainstream " oncogene-induced senescence " ( OIS ) model believed that when melanocytes only have BRAFV600E gene mutations, the cells will stop dividing and form moles .
-
Regeneron more than 900 million US dollars bet on DNA vaccines for cancer and infectious diseases
Time of Update: 2021-12-04
Recent popular reports from Yimaike ★ Invitation Letter 2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ In vitro lentiviral gene therapy presents positive test results, striving to free patients from the burden of chronic treatment Yimai Meng broke the news in November 2021 29th/eMedClub News/--Nykode Therapeutics recently announced that it has reached a cooperation agreement with Regeneron on the development of cancer and infectious disease vaccines .
-
Express Junshi Biologics anti-PD-1 monoclonal antibody is approved as first-line treatment for nasopharyngeal carcinoma in China
Time of Update: 2021-12-04
According to publicly available information, the new indications approved this time are: Teriprizumab combined with chemotherapy for advanced first-line recurrent and metastatic nasopharyngeal carcinoma (NPC) that has not received systemic treatment .
-
Clin Cancer Res: Nivolumab combined with Ipilimumab in the treatment of advanced metaplastic breast cancer
Time of Update: 2021-12-04
There are no new safety issues when combined treatment with ipilimumab and nivolumab in advanced chemotherapy-refractory MpBC patients, and an objective response rate of 18% as the primary endpoint is achieved .
-
Sci Adv: This cheap oral drug has doubled the effect of radiotherapy for cancer brain metastases!
Time of Update: 2021-12-04
Science Advances The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastasesThe study is a proof-of-concept randomized clinical trial that reports the results of oral arginine given before standard radiotherapy for 31 patients with brain metastases .
-
What should we know about MET targets?
Time of Update: 2021-12-04
Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations[J].
MET 14 Research progress of exon skipping mutation in non-small cell lung cancer[J].
-
[JAMA Sub-Journal] Patient-led surveillance-the prospects of melanoma care
Time of Update: 2021-12-04
Professor Monika Janda from the University of Queensland Health Service Research Center said that in a randomized preliminary study, the patient-led surveillance team detected 5 new cases of melanoma before clinical visits .
-
Non-small cell lung cancer (NSCLC): emerging therapeutic targets and therapeutic drugs
Time of Update: 2021-12-04
KRAS G12C-mediated tumor proliferation pathway and the mechanism of action of KRAS G12C inhibitors Although therapies targeting EGFR and ALK have been developed and proven effective, although the therapeutic effects are different, there are few options for KRAS mutations .
-
Clin Cancer Res: Activity and safety of third-generation EGFR-TKI Abvertinib in the treatment of EGFR T790M+ NSCLC
Time of Update: 2021-12-04
It aims to clarify the maximum recommended dose (RP2D) of Abvertinib in the Phase 1 trial; evaluate Abvertinib for past acceptance in the Phase 2 trial The activity and safety of NSCLC patients with EGFR T790M mutation who have advanced disease after treatment with EGFR inhibitors .
-
Gut Microbes: Real hammer!
Time of Update: 2021-12-04
Recently, researchers at the Karolinska Institute in Sweden " Gut Microbes published on" an article entitled "Isolation ofpancreatic microbiota from cystic precursors of pancreatic cancer withintracellular growth and DNA damaging properties" papers, they found that from the digestive tract The bacteria seem to cause damage to pancreatic cells and increase the risk of malignant tumors .
-
European Radiology: Prognostic value of MRI parapharyngeal subspace involvement in nasopharyngeal carcinoma
Time of Update: 2021-12-04
Previous studies have explored the impact of PPSI sub-categories on the prognosis of nasopharyngeal carcinoma, based on the division of the parapharyngeal space into two intervals, such as the prepharyngeal space and the posterior pharyngeal space , the carotid artery sheath (CS) and the area outside the CS , Parapharyngeal part and parapharyngeal part .
-
Bispecific cancer immunotherapy!
Time of Update: 2021-12-04
Recommended reading: ASH 2020: Regeneron CD20/CD3 double antibody shows positive clinical data, with CAR-T cells as a potential competitor Yimai Meng broke the news on June 10, 2020, AbbVie and Genmab announced Reached a cooperation to jointly develop Genmab’s three next-generation bispecific antibody products, including CD3/CD20 bi-antibody epcoritamab (currently undergoing clinical trials for B-cell non-Hodgkin’s lymphoma).
-
Lancet Gastroenterol Hepatol: Colorectal cancer incidence, mortality, staging and treatment before and after the stool immunohistochemical test screening program
Time of Update: 2021-12-04
Calculated the age-standardized incidence of colorectal cancer, the Netherlands and the use of statistical data to calculate the Bureau 2010 - related mortality of colorectal cancer in 2019; also compared the screening detection of colorectal cancer, 2014--2018 years of clinical examination The location, stage distribution and treatment of colorectal cancer in 55-75-year-old patients .
